
SGMT Stock Forecast & Price Target
SGMT Analyst Ratings
Bulls say
Sagimet Biosciences is demonstrating promising developments in its clinical-stage pipeline, particularly with its lead candidate, denifanstat, which has shown significant anti-fibrotic effects in patients with nonalcoholic steatohepatitis (NASH) and has been associated with improvements in cardiovascular health markers. The recent clearance of the IND application for Sagimet's second FASN inhibitor, TVB-3567, further highlights the potential for diversification in treating dermatological conditions such as acne, reinforcing investor confidence in the company's innovative therapeutics. Additionally, positive interim data from ongoing trials underscore the effectiveness of denifanstat in improving crucial liver parameters, suggesting a strong position for future commercialization and revenue generation.
Bears say
Sagimet Biosciences Inc reported a net loss of $16.2 million for the fourth quarter of 2024, with a loss per share of $0.50, highlighting the ongoing financial struggles faced by the company. The investment outlook is marred by significant risks including the potential for disappointing Phase 3 trial results for its lead drug candidate, denifanstat, and challenges in securing regulatory approval in the U.S. Additionally, concerns about a smaller than expected commercial market opportunity, development delays, and funding capabilities further contribute to a negative sentiment toward the stock.
This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SGMT Analyst Forecast & Price Prediction
Start investing in SGMT
Order type
Buy in
Order amount
Est. shares
0 shares